Dear Shareholder,
The board of directors (the “Board“) of IGEA Pharmal N.V. (the “Company“) hereby invites you to attend the virtual annualgeneral meeting on 9 July 2021 (the “AGM“). The meeting will start at 10:00 hours CEST and is to be attended virtually Registration will start at 9:30 hours CEST.
Minutes of the Extraordinary General Meeting of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands) and address at (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821, held virtually on 28 April 2021.
Dear Shareholder,
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites you to attend the virtual extraordinary general meeting on 28 April 2021 (the “EGM”). The meeting will start at 10:00 hours CEST and is to be attended virtually. Registration will start at 9:30 hours CEST.
This press release complements today’s announcement “IGEA calls extraordinary general meeting” to be viewed on https://www.igeapharma.nl/category/press-releases.
Hoofddorp, the Netherlands, 22 March 2021. IGEA Pharma N.V. (SIX: IGPH) today announced important changes in its board of directors. As announced today by separate press release, new persons were bindingly nominated for election as non-executive directors in the board of IGEA at the upcoming extraordinary general meeting of 28 April 2021.
Minutes of the Extraordinary General Meeting of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands) and address at (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821, held at Hoofddorp Transpolis, Polarisavenue 1, (2123 JH) Hoofddorp (the Netherlands) on 3 July 2020.
Dear Shareholder,
The board of directors (the “Board”) of IGEA Pharma N.V. (the “Company”) hereby invites you to attend the general meeting on 3 July 2020 (the “GM”) at Hoofddorp Transpolis, Polarisavenue 1, 2123 JH Hoofddorp, the Netherlands. The meeting will start at 10:00 hours CEST. Registration will start at 9:30 hours CEST. Due to the current ongoing situation with COVID-19, the Company encourages its shareholders to attend the GM by proxy.
Minutes of the Extraordinary General Meeting of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands) and address at (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821, held at Hoofddorp Transpolis, Polarisavenue 1, (2123 JH) Hoofddorp (the Netherlands) on 8 January 2020.
Dear Shareholder,
The Management Board of IGEA Pharma N.V. (the “Company”) hereby invites you to attend the extraordinary general meeting on 8 January 2020 (the “EGM”). The meeting will be held at Hoofddorp Transpolis, Polarisavenue 1, 2123 JH Hoofddorp, the Netherlands. The meeting will start at 10:00 hours CET. Registration will start at 9:30 hours CET.
This press release complements today’s announcement “IGEA calls extraordinary general meeting” to be viewed here.
Hoofddorp, the Netherlands, 3 December 2019. IGEA Pharma N.V. (SIX: IGPH) today announced changes in its supervisory board. As announced today by separate press release, IGEA proposes to its shareholders to amend the articles of association by introducing a one-tier board structure with executive and non-executive directors. The current supervisory board will be abolished as a corporate body in connection with this proposed amendment. Giovanni Ferrario and Mark de Simone, chairman and member, respectively, of the current supervisory board, will stand for election as non-executive directors. Federico Bazzoni and Flavio Peralda resigned and will no longer serve as directors.
Minutes of the first annual general meeting of IGEA Pharma N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands, having its corporate seat at Hoofddorp, the Netherlands (the “Company”), held on 6 June 2019 at 10:00 am CET at Hoofddorp Transpolis, Polarisavenue 1, 2123 JH Hoofddorp, the Netherlands (the “Meeting”).